Advances in Pulmonary Arterial Hypertension: Emerging Therapies and Clinical Outcomes

Dear Colleagues,

Pulmonary arterial hypertension (PAH) is a progressive and life-threatening condition, and recent years have seen substantial advances that are reshaping its clinical management. The approval of novel agents such as sotatercept, the development of innovative inhaled therapies, and the expansion of therapeutic options emerging from ongoing clinical trials have marked an important shift in the treatment landscape of PAH. These advances raise critical questions regarding how new therapies can be optimally integrated into current treatment strategies and how they may influence patient management. Early-stage disease and complex phenotypes are difficult to recognize or classify, advances in imaging, hemodynamic assessment, and risk stratification strategies, biomarkers, genetic testing have further expanded diagnostic possibilities and improved early detection.

This Special Issue, “Advances in Pulmonary Arterial Hypertension: Emerging Therapies and Clinical Outcomes,” aims to provide a focused platform for high-quality contributions examining recent progress in PAH treatment. We particularly welcome papers addressing emergingdiagnostic tools, pharmacological therapies, their mechanisms of action, and their role within current therapeutic strategies. Studies evaluating treatment response, disease progression, and evidence from clinical trials or real-world practice are also encouraged. Original research articles and reviews that advance understanding of contemporary PAH therapy and future treatment directions are invited.

Dr. Namita Sood
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the Special Issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.